What is Access Biologicals?
Access Biologicals operates as a critical infrastructure provider for the pharmaceutical and diagnostic manufacturing sectors. By leveraging an extensive network of plasma and blood collection centers across the United States and Europe, the company delivers high-purity biological materials essential for cell therapy, in vitro diagnostic (IVD) manufacturing, and advanced research and development. Their commitment to rigorous safety protocols and regulatory compliance positions them as a preferred partner for organizations requiring consistent, high-quality human-derived proteins and clinical samples. As the demand for sophisticated biological inputs continues to rise, Access Biologicals remains a cornerstone of the life science research ecosystem.
How much funding has Access Biologicals raised?
Access Biologicals has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Access Biologicals
PPP
Public-Private Partnership
What's next for Access Biologicals?
With this major enterprise-level funding, Access Biologicals is poised to scale its procurement network and enhance its processing capabilities. The strategic allocation of this capital will likely focus on expanding the company's reach in international markets and optimizing its supply chain logistics to meet the increasing requirements of the biotech industry. By strengthening its core infrastructure, the firm aims to solidify its market leadership, ensuring that it can support the next generation of therapeutic breakthroughs and diagnostic innovations with reliable, compliant biological assets.
See full Access Biologicals company page
